Literature DB >> 9843884

Antagonism of ANG II type 1 receptors protects the endothelium during the early stages of renal hypertension in rats.

J Hoshino1, T Nakamura, T Kurashina, Y Saito, H Sumino, Z Ono, H Sakamoto, K Kowase, R Nagai.   

Abstract

The degree of involvement of the renin-angiotensin system in endothelial dysfunction was investigated by using a one-kidney, one-clip (1K,1C) model of renal hypertension. Male Wistar rats received 0.02% enalapril, 0.02% losartan, or tap water for 1 day before and for 48 h after the induction of renal artery stenosis or sham operation. The aorta of 1K,1C rats showed increased contraction and decreased relaxation responses produced by norepinephrine and acetylcholine, respectively, vs. control responses. Exposure to 10(-5) mol/l NG-monomethyl-L-arginine acetate augmented the contractile responses to norepinephrine to a greater extent in control rats than in the 1K,1C rats. The increased contraction and decreased relaxation responses to these agonists in the 1K,1C rats were normalized by enalapril or losartan. The addition of HOE-140 to the bath did not alter these normalized responses. Results suggest that angiotensin II causes endothelial dysfunction and reduces nitric oxide levels in 1K,1C rats. Such endothelial dysfunction enhanced the norepinephrine-induced contraction during the early-stage hypertension in 1K,1C rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843884     DOI: 10.1152/ajpregu.1998.275.6.R1950

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

Review 1.  Effects of antihypertensive therapy on hypertensive vascular disease.

Authors:  J B Park; E L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

2.  Elevated pressure selectively blunts flow-evoked vasodilatation in rat mesenteric small arteries.

Authors:  F H Christensen; T Hansen; E Stankevicius; N H Buus; U Simonsen
Journal:  Br J Pharmacol       Date:  2006-11-27       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.